Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection

Yuehan Zhang, Tim Waterboer, Michael Pawlita, Elizabeth Sugar, Howard Minkoff, Ross D. Cranston, Dorothy Wiley, Robert D. Burk, Susheel Reddy, Joseph Margolick, Howard Strickler, Kathleen Weber, Maura Gillison, Gypsyamber D'Souza

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction Human Papillomavirus (HPV) 16 E6 serum antibodies are common in people with HPV-related oropharyngeal cancers (HPV-OPC), but not the general population. We explored HPV16 seroprevalence in people with and without oral HPV16 infection, the cause of HPV-OPC. Methods Oral rinse samples were collected semiannually and tested for 36 types of HPV DNA by PCR. HPV16 E6 serum antibodies were tested at the visit of first oral HPV detection in participants with prevalent (n = 54), or incident (n = 39) oral HPV16 DNA; or at baseline in matched participants with no oral HPV16 DNA (n = 155) using multiplex serology assay. Predictors of seropositivity were examined using logistic regression. Results HPV16 E6 seropositivity (7.5% vs 0.7%; p = 0.005) but not seropositivity to the other HPV16 antigens, was significantly more common in those with than without oral HPV16 infection. There were only 8 HPV16 E6 seropositive participants, but oral HPV16 DNA remained a strong predictor of E6 seropositivity after adjustment for other risk factors (aOR = 14.6 95%CI, 1.7–122.5). Seroprevalence was similar in those with prevalent (7.4%; 4/54), and incident (7.7%; 3/39) oral HPV16 infection (p = 1.00). E6 seroprevalence was associated with reduced oral HPV16 clearance, but was not statistically significant (HR = 0.65 95% CI, 0.16–2.70). Seropositive participants were primarily male (87.5%), HIV-positive (75.0%; median CD4 cell-count of 840) and had oral HPV16 DNA (87.5%). History of an HPV-related cancer (0/8) or HPV-related anogenital dysplasia (1/8) was rare, and 4 participants had recent screening showing no anogenital dysplasia. Discussion HPV16 E6 seropositivity was higher among people with than without oral HPV16 infection, despite no known anogenital disease in these participants.

Original languageEnglish (US)
Pages (from-to)30-34
Number of pages5
JournalCancer Epidemiology
Volume43
DOIs
StatePublished - Aug 1 2016

Fingerprint

Human papillomavirus 16
Seroepidemiologic Studies
Infection
DNA
Oropharyngeal Neoplasms
Antibodies
Serology
CD4 Lymphocyte Count
Serum
Logistic Models
HIV
Antigens
Polymerase Chain Reaction
Population
Neoplasms

Keywords

  • Antibodies
  • Biomarker
  • HPV16 E6
  • Oral HPV
  • Seroprevalence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology

Cite this

Zhang, Y., Waterboer, T., Pawlita, M., Sugar, E., Minkoff, H., Cranston, R. D., ... D'Souza, G. (2016). Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection. Cancer Epidemiology, 43, 30-34. https://doi.org/10.1016/j.canep.2016.06.002

Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection. / Zhang, Yuehan; Waterboer, Tim; Pawlita, Michael; Sugar, Elizabeth; Minkoff, Howard; Cranston, Ross D.; Wiley, Dorothy; Burk, Robert D.; Reddy, Susheel; Margolick, Joseph; Strickler, Howard; Weber, Kathleen; Gillison, Maura; D'Souza, Gypsyamber.

In: Cancer Epidemiology, Vol. 43, 01.08.2016, p. 30-34.

Research output: Contribution to journalArticle

Zhang, Y, Waterboer, T, Pawlita, M, Sugar, E, Minkoff, H, Cranston, RD, Wiley, D, Burk, RD, Reddy, S, Margolick, J, Strickler, H, Weber, K, Gillison, M & D'Souza, G 2016, 'Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection', Cancer Epidemiology, vol. 43, pp. 30-34. https://doi.org/10.1016/j.canep.2016.06.002
Zhang, Yuehan ; Waterboer, Tim ; Pawlita, Michael ; Sugar, Elizabeth ; Minkoff, Howard ; Cranston, Ross D. ; Wiley, Dorothy ; Burk, Robert D. ; Reddy, Susheel ; Margolick, Joseph ; Strickler, Howard ; Weber, Kathleen ; Gillison, Maura ; D'Souza, Gypsyamber. / Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection. In: Cancer Epidemiology. 2016 ; Vol. 43. pp. 30-34.
@article{c00e7aae62d24be3b17750c803a3a6d0,
title = "Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection",
abstract = "Introduction Human Papillomavirus (HPV) 16 E6 serum antibodies are common in people with HPV-related oropharyngeal cancers (HPV-OPC), but not the general population. We explored HPV16 seroprevalence in people with and without oral HPV16 infection, the cause of HPV-OPC. Methods Oral rinse samples were collected semiannually and tested for 36 types of HPV DNA by PCR. HPV16 E6 serum antibodies were tested at the visit of first oral HPV detection in participants with prevalent (n = 54), or incident (n = 39) oral HPV16 DNA; or at baseline in matched participants with no oral HPV16 DNA (n = 155) using multiplex serology assay. Predictors of seropositivity were examined using logistic regression. Results HPV16 E6 seropositivity (7.5{\%} vs 0.7{\%}; p = 0.005) but not seropositivity to the other HPV16 antigens, was significantly more common in those with than without oral HPV16 infection. There were only 8 HPV16 E6 seropositive participants, but oral HPV16 DNA remained a strong predictor of E6 seropositivity after adjustment for other risk factors (aOR = 14.6 95{\%}CI, 1.7–122.5). Seroprevalence was similar in those with prevalent (7.4{\%}; 4/54), and incident (7.7{\%}; 3/39) oral HPV16 infection (p = 1.00). E6 seroprevalence was associated with reduced oral HPV16 clearance, but was not statistically significant (HR = 0.65 95{\%} CI, 0.16–2.70). Seropositive participants were primarily male (87.5{\%}), HIV-positive (75.0{\%}; median CD4 cell-count of 840) and had oral HPV16 DNA (87.5{\%}). History of an HPV-related cancer (0/8) or HPV-related anogenital dysplasia (1/8) was rare, and 4 participants had recent screening showing no anogenital dysplasia. Discussion HPV16 E6 seropositivity was higher among people with than without oral HPV16 infection, despite no known anogenital disease in these participants.",
keywords = "Antibodies, Biomarker, HPV16 E6, Oral HPV, Seroprevalence",
author = "Yuehan Zhang and Tim Waterboer and Michael Pawlita and Elizabeth Sugar and Howard Minkoff and Cranston, {Ross D.} and Dorothy Wiley and Burk, {Robert D.} and Susheel Reddy and Joseph Margolick and Howard Strickler and Kathleen Weber and Maura Gillison and Gypsyamber D'Souza",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.canep.2016.06.002",
language = "English (US)",
volume = "43",
pages = "30--34",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection

AU - Zhang, Yuehan

AU - Waterboer, Tim

AU - Pawlita, Michael

AU - Sugar, Elizabeth

AU - Minkoff, Howard

AU - Cranston, Ross D.

AU - Wiley, Dorothy

AU - Burk, Robert D.

AU - Reddy, Susheel

AU - Margolick, Joseph

AU - Strickler, Howard

AU - Weber, Kathleen

AU - Gillison, Maura

AU - D'Souza, Gypsyamber

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Introduction Human Papillomavirus (HPV) 16 E6 serum antibodies are common in people with HPV-related oropharyngeal cancers (HPV-OPC), but not the general population. We explored HPV16 seroprevalence in people with and without oral HPV16 infection, the cause of HPV-OPC. Methods Oral rinse samples were collected semiannually and tested for 36 types of HPV DNA by PCR. HPV16 E6 serum antibodies were tested at the visit of first oral HPV detection in participants with prevalent (n = 54), or incident (n = 39) oral HPV16 DNA; or at baseline in matched participants with no oral HPV16 DNA (n = 155) using multiplex serology assay. Predictors of seropositivity were examined using logistic regression. Results HPV16 E6 seropositivity (7.5% vs 0.7%; p = 0.005) but not seropositivity to the other HPV16 antigens, was significantly more common in those with than without oral HPV16 infection. There were only 8 HPV16 E6 seropositive participants, but oral HPV16 DNA remained a strong predictor of E6 seropositivity after adjustment for other risk factors (aOR = 14.6 95%CI, 1.7–122.5). Seroprevalence was similar in those with prevalent (7.4%; 4/54), and incident (7.7%; 3/39) oral HPV16 infection (p = 1.00). E6 seroprevalence was associated with reduced oral HPV16 clearance, but was not statistically significant (HR = 0.65 95% CI, 0.16–2.70). Seropositive participants were primarily male (87.5%), HIV-positive (75.0%; median CD4 cell-count of 840) and had oral HPV16 DNA (87.5%). History of an HPV-related cancer (0/8) or HPV-related anogenital dysplasia (1/8) was rare, and 4 participants had recent screening showing no anogenital dysplasia. Discussion HPV16 E6 seropositivity was higher among people with than without oral HPV16 infection, despite no known anogenital disease in these participants.

AB - Introduction Human Papillomavirus (HPV) 16 E6 serum antibodies are common in people with HPV-related oropharyngeal cancers (HPV-OPC), but not the general population. We explored HPV16 seroprevalence in people with and without oral HPV16 infection, the cause of HPV-OPC. Methods Oral rinse samples were collected semiannually and tested for 36 types of HPV DNA by PCR. HPV16 E6 serum antibodies were tested at the visit of first oral HPV detection in participants with prevalent (n = 54), or incident (n = 39) oral HPV16 DNA; or at baseline in matched participants with no oral HPV16 DNA (n = 155) using multiplex serology assay. Predictors of seropositivity were examined using logistic regression. Results HPV16 E6 seropositivity (7.5% vs 0.7%; p = 0.005) but not seropositivity to the other HPV16 antigens, was significantly more common in those with than without oral HPV16 infection. There were only 8 HPV16 E6 seropositive participants, but oral HPV16 DNA remained a strong predictor of E6 seropositivity after adjustment for other risk factors (aOR = 14.6 95%CI, 1.7–122.5). Seroprevalence was similar in those with prevalent (7.4%; 4/54), and incident (7.7%; 3/39) oral HPV16 infection (p = 1.00). E6 seroprevalence was associated with reduced oral HPV16 clearance, but was not statistically significant (HR = 0.65 95% CI, 0.16–2.70). Seropositive participants were primarily male (87.5%), HIV-positive (75.0%; median CD4 cell-count of 840) and had oral HPV16 DNA (87.5%). History of an HPV-related cancer (0/8) or HPV-related anogenital dysplasia (1/8) was rare, and 4 participants had recent screening showing no anogenital dysplasia. Discussion HPV16 E6 seropositivity was higher among people with than without oral HPV16 infection, despite no known anogenital disease in these participants.

KW - Antibodies

KW - Biomarker

KW - HPV16 E6

KW - Oral HPV

KW - Seroprevalence

UR - http://www.scopus.com/inward/record.url?scp=84975795692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975795692&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2016.06.002

DO - 10.1016/j.canep.2016.06.002

M3 - Article

C2 - 27344614

AN - SCOPUS:84975795692

VL - 43

SP - 30

EP - 34

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

ER -